Nomenclature: SCP-tags: solubility controlling peptide tags; We use "aggregates" and "oligomer" interchangeably. Sub-visible aggregates/oligomers: Aggregates/oligomers ~<100 µm that are not visible to the naked eye and remain in the soluble fraction upon 2 centrifugation; : A simplified variant of bovine pancreatic trypsin inhibitor containing 19 alanines; BPTI-C5X: 5 amino acid residues as SCP-tags added at the C-terminus of BPTI, where X stands for amino acid identity.
Introduction
Therapeutic proteins such as monoclonal antibodies, hormones, and other recombinant protein drugs are increasingly used for the treatment of various types of human diseases. However, protein aggregation, causing unwanted immunogenicity against therapeutic proteins 1,2 and in turn decreasing therapeutic efficacy through the production of anti-drug antibodies, has occasionally been reported 3-5 . In general, monomeric proteins in any state (native, partially unfolded, or unfolded) may form aggregates of diverse sizes ranging from tiny sub-visible aggregates to visible precipitates with various biophysical properties 6-9 . Hence, it is worth exploring the nature of the relationship between the aggregates and the protein's immunogenicity from a biophysical perspective.
A link between the aggregation of therapeutic proteins and immunogenicity has long been speculated and has been documented especially for micron-size sub-visible aggregates 10-13 For example, in vitro experiments indicated that 2-10 µm sized sub-visible aggregates of human monoclonal antibodies increased the production of naïve peripheral blood mononuclear cells 14 .
Likewise, Trastuzumab (a monoclonal antibody) with less than 3% of ~2 µm sub-visible aggregates, caused T-cell proliferation in vitro 15 . In vivo investigations are less common, and experiments using mice models showed that sub-visible aggregates of a humanized ScFv generated immunogenicity 16, 17 . However, other immunization studies revealed that aggregates of antibodies 18 or proteins 19 are not always immunogenic. One factor behind the lack of consistency is that the micron-aggregates are induced by chemical and physical stresses 20, 21 making it difficult to control their biophysical characteristics. Furthermore, the aggregates assessed in samples are different from the injected ones 21, 22 or in many other reports the sizes are not measured at all 23-25 . As a consequence, the biophysical properties (structure, stability, conformation, etc.) of aggregates responsible for the increased immune response are yet to be fully elucidated 1,13,17, 21 .
Recently, the European Medicines Agency (EMA) considered visible and sub-visible aggregates as risk factors for unwanted immunogenicity of therapeutic proteins in their safety guidelines 26 . Likewise, the Food and Drug Administration (FDA) recommended the screening and minimizing of sub-visible aggregates within 2-10 µm ranges 27 . These recommendations are based on several clinical reports suspecting that aggregates of therapeutic proteins might have caused adverse immune response. However, clinical case reports are inherently contextual and often put little emphasis on the biophysical properties of the therapeutic proteins 28-30 .
Additionally, the immune response generated by protein aggregates smaller than 2 µm is practically un-investigated, due to technical burdens for identifying and measuring them.
In previous reports, we showed, using BPTI-19A as a model protein (58 residues; MW: 5.98 kDa), that one can manipulate a protein's solubility 31-33 , aggregation kinetics 34 and aggregate sizes 35 by using a solubility controlling peptide tag (SCP-tag). The advantage of the SCP-tags is that we can control the size and properties of the aggregates rather accurately and that the tags do not affect or barely affects the thermodynamic properties, structure, and function of the native protein 32,33, 36 . In this study, we investigated the immunogenicity of BPTI-19A that were oligomerized into nanometer-sized sub-visible aggregates by attaching hydrophobic SCP-tags (C5A, C5V, C5L and C5I). As a result, the untagged BPTI-19A was not immunogenic as assessed by IgG ELISA against BPTI-19A, but a minute increase of the hydrodynamic radius to ~4 nm, which was generated by attaching a C5I tag to BPTI-19A, increased its immunogenicity by up to 66 folds. These observations indicate that nanometer-size aggregates, which are much smaller than currently examined aggregates and that are difficult to remove by filtration/centrifugation as used in standard biomedical practices, can significantly increase the immunogenicity of a therapeutic protein.
Results and Discussion

Oligomerization of BPTI-19A using SCP-tags
The size of the aggregates was measured by dynamic light scattering at both 25 and 37 °C. The samples were prepared in PBS, kept for 20 minutes at 25 °C, and centrifuged at 20,000xg for 20 minutes at 25 °C to remove large particles if any (see Materials and Methods for details).
The concentrations of the BPTI variants remained nearly unchanged upon centrifugation or filtration with a 0.2 µm Minisart filter (Supplementary Figure S1a) , confirming that only submicron and soluble aggregates were present in the samples. The Rh of the untagged BPTI-19A, C5A, and C5V tagged variants at 25 °C were 1.33±0.02 nm, 1.46±0.05 nm, and 1.34±0.02 nm, respectively, and remained almost unchanged at 37 °C (Table 1) ; the C5L tag increased the Rh to 2.11±0.14 nm, and the C5I tag increased the Rh to 3.12±0.06 nm at 25 °C (Figure 2a and Table 1 ). All three 5 Ile-tagged variants (N5I, C5I, and ssC5I) formed aggregates with similar hydrodynamic radii (Rh ~3.12 nm to ~3.97 nm) at 37 °C ( Table 1 and Supplementary Figure   S1b ). Importantly, the sizes of the sub-visible aggregates analyzed just before immunization remained almost constant from dose to dose (Figure 2b) . These observations clearly suggested that the increased hydrodynamic radii observed for the C5I-tagged BPTI originated from the SCP-tag attachment. The overall order of hydrodynamic radii at 37 °C was thus BPTI-19A<C5A/C5V<C5L<N5I<C5I/ssC5I ( Table 1 and Supplementary Figure S1b Figure   S1d ).
In addition to DLS and SLS, the sizes of the aggregates were determined by sedimentation velocity experiment using analytical ultra centrifugation (AUC). The results showed that at 33 °C BPTI-19A and C5A had homogenous average molecular weights of ~6 kDa indicating that they are monomers. C5V was also nearly homogenous with an average molecular weight of ~8 kDa (Figure 2d and Table 2 ). However, C5L and N5I contained an oligomeric populations. In particular, ssC5I, which had the largest Rh showed various species of aggregates existed in the solution, and the average molecular weight of the aggregates was estimated to be ~230 kDa. 7 Altogether, AUC and the SLS results were in good agreement with the DLS observations where C5I tag induced the highest oligomeric size, intensity and molecular weight.
Effects of SCP-tags on the structures of BPTI variants
The impacts of SCP-tags on the conformational stability of BPTI-19A were investigated using Tyr-fluorescence and CD under conditions identical to those used for DLS (0.3 mg/mL in PBS, pH 7.4). Fluorescence spectra showed that all BPTI variants maintained native conformation except C5I/ssC5I which quenched the tyrosine fluorescence at 25 and 37 °C (Figure 3a and 3b, Supplementary Figure S2a ). Additionally, the fluorescence of C5L showed a marginal reduction when the temperature was increased to 37 °C. We can interpret this quenching as a partial denaturation, where the tyrosine residues are becoming exposed to water molecules and their mobility increase 38 Note that, all the variants showed reversibility when the temperature was cooled back to 4 °C (Supplementary Figure S2b To understand the effect of secondary structural changes on the conformation of BPTI variants CD measurements were carried out and the supernatants' spectra at 25 and 37 °C revealed that none of the SCP-tags affected the native-like secondary structure contents, except C5I/ssC5I (Figure 3c and 3d, Supplementary Figure S2d -S2j) which was slightly denatured at 25 and 37 °C (C5L was partially denatured at 37 °C but not at 25 °C in line with the above tyrosine fluorescence results). This partial denaturation occurs because of the hydrophobic environment created by the hydrophobic tags upon BPTI-19A's oligomerization and we related this to a multi-molecular reversed hydrophobic effect 39 . The association was reversible when CD spectra were measured at low concentration or temperature, and the tagged BPTI variants are fully folded as previously assessed by Trypsin inhibition assay performed at 280 nM 35 . Thus, the present results confirm the reversible association of all SCP-tagged BPTI-19A variants, which retain a native-like structure in the monomeric state, and they suggest that the SCP-tags did not affect the native biophysical properties of BPTI-19A, except producing temperaturedependent nanometer-size sub-visible aggregates under inoculation condition used in the present study. 8 
Effects of nanometer size aggregates on protein immunogenicity
We investigated the sizes of SCP-tag induced sub-visible aggregates on the immunogenicity of BPTI-19A in Jcl: ICR mice by ELISA. Both in the presence and absence of adjuvant, the untagged BPTI-19A with Rh ~1.34 nm was essentially non-immunogenic (Supplementary Figure S3a) , as expected for a small protein. Similarly, no immune response was observed during the first two doses for any of the variants even in the presence of adjuvant. However, after the third dose, the antibody titers of the tagged BPTIs started to increase (Figure 4a) , and after the final dose, the heart-bleed sera of C5I/ssC5I exhibited the highest absorbance at 492 nm (Figure 4b ). C5A and C5V having Rh close to untagged 19A (Rh ~1.5 nm) and C5L which was slightly larger (Rh ~2.3 nm) than that of the untagged BPTI-19A, increased the immunogenicity by 15-23 fold. Upon a further increase of the hydrodynamic radius to ~3.7 nm by attaching the 5-Ile tags, the anti-BPTI-19A titers increased over 55 fold ( Table 3 and Supplementary Figure S3b ), in line with their aggregate sizes and SLS intensities (Figure 4c and Supplementary Figure S3c ). Notably, ssC5I (Rh ~3.96 nm) also enhanced the titer by 66 fold indicating that the increase in antibody titers observed with 5-residue Ile-tag was independent of the type of residues (Gly or Ser) used as a spacer. On the other hand, the Nterminus-tagged BPTI-N5I increased the IgG titer only 22 fold which was almost one-third of the average titer observed for C5I (N5I also formed smaller aggregates than C5I, Rh ~3.13 nm).
Noteworthy, the antibody responses were directed against the BPTI-19A and not against the tag sequence as demonstrated by the ELISA signals, obtained with plates coated with BPTI-19A without a tag or BPTI-19A with their respective tags, self-tags. (Supplementary Figure   S3d ). Immunization experiments in the absence of adjuvant showed similar results, in which C5I increased the antibody titer of BPTI-19A by 90 to 222 fold (Figure 4d and Table 3 ). Thus, the effect of the tags was comparable, and furthermore cumulative, to that of the traditional Freund's adjuvant (Supplementary Figure S3e) , confirming the strong potential of SCP-tag as a target-specific adjuvant.
Immune response maintenance and immunogenic memory
Finally, we assessed the long-term maintenance of the immune responses generated by the untagged BPTI-19A and BPTI-C5I. Mice were injected with three consecutive doses at 3-week intervals, kept untreated for 70 days (10 weeks), but during this period the IgG level was measured weekly through tail-bleeding. Anti-BPTI-19A IgG levels, as measured by ELISA, remained high over 8 weeks for the mice injected with C5I, before declining. Furthermore, BPTI-19A memory was generated by the aggregates. Seventy days after the 3 rd dose, the 4 th dose of C5I boosted the IgG titers by 2300-3600 fold, whereas the response of mice immunized with the untagged BPTI-19A remained almost nil throughout the entire immunization scheme (Figure 4e) . Altogether, these observations indicated that the immune response was longlasting and further that B-cell immune memory was established.
SCP-tags for biophysical and immunological study
A link between protein aggregation and immunogenicity has been suspected for a long time, however, without reaching a strong consensus. The lack of consistency was often blamed on to the inherent disparity arising from in vivo experiments, but it appears that in many reports, the sample condition might not have been sufficiently controlled or even measured. From this viewpoint, the nanometer-size sub-visible aggregates produced by attaching hydrophobic SCPtags, are well controlled and avoid the random events encountered by aggregates produced by physical or chemical stresses. Furthermore, we carefully assessed the aggregates' size and its stability upon temperature, pH, protein concentration and type of tags. We further performed a near "real-time" monitoring of the hydrodynamic radius of the aggregates 40 just before each round of inoculation. We believe that such monitoring of the aggregates' size is essential as these aggregates may grow and dissociate upon small variation of external factors.
Consequently, SCP-tags combined with our "real-time" monitoring protocol could provide a new tool for producing aggregates in a stable manner and analyzing the effect of aggregation on immunogenicity, from a biophysical viewpoint.
Conclusion
The effects of sub-visible aggregates of a few nanometers dimension on a protein's immunogenicity have mostly been ignored due to technical challenges in isolating, characterizing, and monitoring them. To the best of our knowledge, this is the first report showing as directly as currently possible, that aggregates as small as a few nanometers (Rh <5 nm) can convert a non-immunogenic protein into a highly immunogenic one. Aggregates smaller than 0.2 µm (200 nm) cannot be removed by filtering using standard filters or centrifugation, and our study thus emphasizes the usefulness of monitoring the presence of small oligomers (or sub-visible aggregates) during the storage and formulation of therapeutic proteins. Finally, the present results show that the SCP-tags can be used to control the aggregates' size in a systematic and stable manner, and as such, they can contribute to a better understanding of the mechanisms underlying aggregation-triggered immunogenicity of proteins.
Materials and Methods
Construction of SCP-tagged BPTI variants (C5A, C5V, C5L, C5I/ssC5I and N5I)
All BPTI variants were constructed with a pMMHa vector 35 . DNA sequences encoding two Gly/Ser residues (serving as a spacer), and the SCP-tags were added to the C-terminus of the template BPTI-19A [a BPTI containing 19 alanines out of its 58 residues 31 sequence using QuikChange site-directed mutagenesis (Stratagene, USA). The plasmid sequences were confirmed by DNA sequencing (ABI PRISM 3130xl Genetic Analyzer, USA). BPTI variants were named according to the number and type of amino acids added to the C-terminus of BPTI-19A (Figure 1) . For example, C5I stands for five Isoleucine residues added after two glycines as a spacer at the C-terminus of BPTI-19A. Similarly, N5I indicates a mutant with five isoleucine added at the N-terminus of BPTI with two glycines as a spacer.
Protein expression, purification and sample preparation
All BPTI variants were expressed in Escherichia coli BL21 (DE3) pLysS cell lines at 37 °C and purified by pI precipitation, followed by reverse phase HPLC as per our previous protocol 35 . Protein identities were confirmed by MALDI-TOF mass spectrometry (AB SCIEX TOF/TOF TM 5800, USA) and the purified proteins were preserved at -30 °C as lyophilized powder. While preparing samples, the lyophilized protein powders were first dissolved at 1mg/mL in MilliQ water (Millipore A10 ultra-pure water purifier, EMD Millipore, Germany) as protein stocks, and the final working sample was prepared in phosphate buffered saline (PBS, pH 7.4-filtered by 0.2 µm Minisart filters) at 0.3 mg/mL concentration as determined by the extinction coefficient (A280) using Nanodrop (Nanodrop-2000, Thermo Fisher Scientific, USA). Stock samples were centrifuged at 20,000xg for 20 minutes at 4 °C. Working samples were kept at 25 °C for 20 minutes and centrifuged just before measurements to remove aggregates, if there was any.
Analysis of sub-visible protein aggregates by dynamic light scattering (DLS), static light scattering (SLS) and analytical ultra-centrifugation (AUC)
The sub-visible aggregates' sizes were measured by preparing the BPTI variants in PBS at 0.3 mg/mL. As mentioned earlier, samples were left still for 20 minutes at 25 °C, centrifuged (20,000xg for 20 minutes at 25 °C), and the supernatants were used for DLS measurements (Malvern Zetasizer Nano-S System, UK). The Rh was measured at 25 and 37 °C and calculated as the average of three independent readings from the number distributions using the Stokes-Einstein equation 41 . The presence of sub-visible aggregates was also monitored using static light scattering (SLS). The intensity of the supernatants was monitored at 600 nm wavelength at 25 and 37 °C with an FP-8500 spectrofluorometer (JASCO, Japan) using a cuvette with a 3 mm optical path length. Each measurement was accumulated three times, and the values were 
Structural analysis of BPTI variants by Tyr Fluorescence and Circular Dichroism (CD) spectroscopy
Tertiary and secondary structures of all BPTI variants were monitored through Tyrfluorescence and CD spectroscopy using an FP-8500 spectrofluorometer and a JASCO J820 
Immunization experiments
The inoculation samples were prepared by dissolving the lyophilized powder in MilliQ water at a concentration of 1 mg/mL. The samples were aliquoted into 10 single-use samples and kept at -30 °C until use. Prior to each inoculation, the samples were slowly thawed at room temperature, reconstituted into the final buffer (PBS) at a concentration of 0.3 mg/ml, incubated for 20 minutes at 25 °C, centrifuged, and the aggregates' sizes were monitored by measuring the Rh at 25 and 37 °C by DLS (see above for measurement details). Three days after each inoculation, ~20 µL of tail-bleed samples were collected and used for measuring the level of anti-BPTI IgG antibodies by using ELISA (see the next section). After the final dose, heart-bleed samples were collected when mice were sacrificed through spinalcord dislocation. These heart-bleed serum samples were preserved in 1:4 dilutions in PBS supplemented with 20% glycerol and stored at -30 °C.
Detection of anti-BPTI responses by ELISA
Anti-BPTI immune response was measured by ELISA using 96-well microtiter plates (TPP micro-titer plates, Japan). HPLC purified untagged BPTI-19A (2.5 µg/mL in PBS) was used for overnight coating of the plate at 25 °C. Unbound proteins were washed out with PBS, and the plates were blocked with 1% BSA in PBS for 45 minutes at 37 °C, followed by washing with PBS once.
Anti-BPTI sera were applied at an initial dilution of 1:50 for the tail-bleed samples, and 1:300 for the heart-bleed samples, followed by 3-fold serial dilution in subsequent wells containing 0.1% BSA-PBS. Plates were then incubated at 37 °C for 2 hours. A positive control was used in all ELISA plates. After washing three times with PBS-0.05% Tween-20, 100μl/well of antimouse IgG HRP conjugate (Thermo Fisher Scientific, USA; at 1:3000 dilution in 0.1% BSA-PBS-Tween-20) was added and incubated at 37 °C for 90 minutes. Finally, unbound conjugates were removed by thoroughly washing three times with PBS-0.05% Tween-20. Coloring was performed by adding the O-phenyl Di-amine (OPD) substrate and incubating for 20 minutes (100 μl/well; OPD 0.4 mg/ml supplemented with 4 mM hydrogen peroxide). Color intensities were measured at 492 nm using a microplate reader (SH-9000 Lab, Hitachi High-Tech Science, Japan) immediately after stopping the reaction with 1 N sulfuric acid (50 µL/well). Values are shown as the average of three independent measurements and three accumulations for DLS and SLS, respectively. Line symbols are explained within the panels. 
Figure legends
